CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 30, 2006--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential technologies for disease research and drug discovery, today introduced a key new product into its successful line of transfection reagents. Lipofectamine(TM) LTX, carrying on the tradition of one of the company’s best-selling technologies - Lipofectamine(TM) 2000 - provides highly effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile.
